Avacta Group (AVCT)
AVCT Share PerformanceMore
|52 week high||98.00 26/05/17|
|52 week low||28.00 11/05/18|
|52 week change||-55.00 (-63.22%)|
|4 week volume||992,815 26/04/18|
Media for (AVCT)
Latest News« previous» nextMore
22/05/2018 - 14:36 StockMarketWire
Avacta Group said a research collaboration with Finland's FIT Biotech had produced 'very encouraging' data relating to its...
22/05/2018 - 07:00 RNS
RNS Number: 7844O Avacta Group PLC 22 May 2018 22 May 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Successful Outcome of "Gene Delivery" Collaboration with FIT Biotech Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits Avacta Group plc (AIM: AVCT), the develop...
30/04/2018 - 16:45 RNS
RNS Number: 6341M Avacta Group PLC 30 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Avacta Group PLC 1...
17/04/2018 - 07:15 RNS
Hardman & Co Research Hardman & Co Research: Avacta (AVCT): Commendable rate of progress 17-Apr-2018 / 07:15 GMT/BST Hardman & Co Research: Commendable rate of progress Avacta is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, w...
16/04/2018 - 08:29 StockMarketWire
Avacta Group, reported Monday a wider half year net loss of 4m, compared with a loss of 3.4m the previous the year, weig...
16/04/2018 - 07:25 RNS
RNS Number: 9356K Avacta Group PLC 16 April 2018 16 April 2018 Avacta Group plc ("Avacta", the "Company" or the "Group") Interim Results for the Period Ended 31 January 2018 Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces its unaudited interim results for the period ended 31 January 2018. Operatin...
09/04/2018 - 14:58 RNS
RNS Number: 3083K Avacta Group PLC 09 April 2018 9 April 2018 Avacta Group plc ("Avacta", "the Group" or "the Company") Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 10,345 new ordinary shares of 10p each (the "New Ordinary Shares") to be ad...
29/03/2018 - 07:00 RNS
RNS Number: 3024J Avacta Group PLC 29 March 2018 29 March 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Present at Proactive Investors One2One Investor Forum Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that the Group's Chief Executive, Alastair Sm...
|Dividend yield||0 %|
Latest discussion posts More
“"The entire process of developing a drug from preclinical research to marketing can take approximately 12 to 18 years and often costs well over $1 billion." That is assuming ...”▼
“up to 20 now! jees lol topped up today bw all mol”▼
“riccardo capital network now on youtube re interims http://www.youtube.com/watch?v=03-RvrK54UI a mighty 4 views - and one mine mol”▼
Codes & Symbols
|Symbols||AVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT|